Pulmonary alveolar hemorrhage from a pulmonary artery false aneurysm after Swan-Ganz catheterization in a thoracic aortic aneurysm patient -a case report-

Daisuke Sugiyama,Shigeo Ikeno,Tetsuya Tsuchihashi,Shigeru Yokota,Hiroaki Ina,Tetsuya Kono,Kunihiko Yamashita,Mikito Kawamata 대한마취통증의학회 2014 Korean Journal of Anesthesiology Vol.67 No.5

Pulmonary artery (PA) rupture caused by a PA Swan-Ganz catheter is a rare complication but remains fatal in almost50% of cases. False aneurysm of the PA is a rare presentation of PA rupture and should be considered as a possible diagnosisin a patient with a new lung mass after PA catheterization. We present a case of sudden-onset pulmonary alveolarhemorrhage during cardiovascular surgery due to a traumatic PA false aneurysm. The Swan-Ganz catheter might havebeen displaced by the thoracic aortic aneurysm with displacement of the catheter causing the false aneurysm and bleeding.

Tropylium Derivatives as New Entrants that Sense Quadruplex Structures

Daisuke Hori,Ji Hye Yum,Hiroshi Sugiyama,Soyoung Park 한국고분자학회 2021 한국고분자학회 학술대회 연구논문 초록집 Vol.46 No.2

G-quadruplex (G4) is the most well-known noncanonical conformation of DNA involved in diverse pharmacological and biological contexts. G4 ligands have been extensively developed as molecular probes and tumor therapeutic reagent candidates. Currently used ligands are commonly aromatic, planar, and electron deficient for effective interaction with quadruplex-stranded DNAs. We recognized that tropylium cations possess the aforementioned features of effective quadruplex ligands. In this study, we prepared tropylium derivatives to validate their binding affinity with G4 and i-motif. Titration experiments revealed interaction between quadruplex structures and tropylium derivatives. We propose tropylium derivatives as new structural motifs indicating quadruplex-specific binding abilities. Our ligands possess the following advantages: small size, facile synthesis, and high solubility in aqueous conditions.

Performance Analysis of a Two-hop Wireless Relay Network with CSMA / CA and Network Coding

Chun-Hsiang Huang,Daisuke Umehara,Satoshi Denno,Masahiro Morikura,Takatoshi Sugiyama 대한전자공학회 2009 ITC-CSCC :International Technical Conference on Ci Vol.2009 No.7

In this paper, we provide an analytical model to compute the approximate throughput of a two-hop wireless relay network in which stations employ carrier sense multiple access with collision avoidance (CSMA/CA) protocol and network coding on the MAC layer. In addition, this model can be applied to the conventional CSMA/CA wireless relay network without network coding. Network coding is a highly regarded technology that is able to enhance the system capacity of multiple unicast and multisource multicast networks. Based on the assumption of no hidden terminals, we show that the proposed analytical model works well with the parameters of IEEE 802.11a and the difference in throughput between theoretical analysis and computer simulation is at most 2 percent.

Development and application of versatile technology for manipulation of chromosome in budding yeast

Yeon-Hee Kim,Daisuke Ishikawa,Minetaka Sugiyama,Yoshinobu Kaneko,Satoshi Harashima 한국생물공학회 2007 한국생물공학회 학술대회 Vol.2007 No.10

Regulation of the embryonic erythropoietic niche: a future perspective

Ayako Yumine,Stuart T. Fraser,Daisuke Sugiyama 대한혈액학회 2017 Blood Research Vol.52 No.1

The production of red blood cells, termed erythropoiesis, occurs in two waves in the developing mouse embryo: first primitive erythropoiesis followed by defin-itive erythropoiesis. In the mouse embryo, both primitive and definitive eryth-ropoiesis originates in the extra-embryonic yolk sac. The definitive wave then mi-grates to the fetal liver, fetal spleen and fetal bone marrow as these organs form. The fetal liver serves as the major organ for hematopoietic cell expansion and er-ythroid maturation after mid-gestation. The erythropoietic niche, which ex-presses critical cytokines such as stem cell factor (SCF), thrombopoietin (TPO) and the insulin-like growth factors IGF1 and IGF2, supports hematopoietic ex-pansion in the fetal liver. Previously, our group demonstrated that DLK1+ hepato-blasts support fetal liver hematopoiesis through erythropoietin and SCF release as well as extracellular matrix deposition. Loss of DLK1+ hepatoblasts in Map2k4-/- mouse embryos resulted in decreased numbers of hematopoietic cells in fetal liver. Genes encoding proteinases and peptidases were found to be highly expressed in DLK1+ hepatoblasts. Capitalizing on this knowledge, and working on the assumption that these proteinases and peptidases are generating small, potentially biologically active peptides, we assessed a range of peptides for their ability to support erythropoiesis in vitro. We identified KS-13 (PCT/JP2010/ 067011) as an erythropoietic peptide-a peptide which enhances the production of red blood cells from progenitor cells. Here, we discuss the elements regulating embryonic erythropoiesis with special attention to niche cells, and demonstrate how this knowledge can be applied in the identification of niche-derived peptides with potential therapeutic capability.

Regulation of the embryonic erythropoietic niche: a future perspective

Ayako Yumine,Stuart T. Fraser,Daisuke Sugiyama 대한혈액학회 2017 Blood Research Vol.52 No.1

The production of red blood cells, termed erythropoiesis, occurs in two waves in the developing mouse embryo: first primitive erythropoiesis followed by defin-itive erythropoiesis. In the mouse embryo, both primitive and definitive eryth-ropoiesis originates in the extra-embryonic yolk sac. The definitive wave then mi-grates to the fetal liver, fetal spleen and fetal bone marrow as these organs form. The fetal liver serves as the major organ for hematopoietic cell expansion and er-ythroid maturation after mid-gestation. The erythropoietic niche, which ex-presses critical cytokines such as stem cell factor (SCF), thrombopoietin (TPO) and the insulin-like growth factors IGF1 and IGF2, supports hematopoietic ex-pansion in the fetal liver. Previously, our group demonstrated that DLK1+ hepato-blasts support fetal liver hematopoiesis through erythropoietin and SCF release as well as extracellular matrix deposition. Loss of DLK1+ hepatoblasts in Map2k4-/- mouse embryos resulted in decreased numbers of hematopoietic cells in fetal liver. Genes encoding proteinases and peptidases were found to be highly expressed in DLK1+ hepatoblasts. Capitalizing on this knowledge, and working on the assumption that these proteinases and peptidases are generating small, potentially biologically active peptides, we assessed a range of peptides for their ability to support erythropoiesis in vitro. We identified KS-13 (PCT/JP2010/ 067011) as an erythropoietic peptide-a peptide which enhances the production of red blood cells from progenitor cells. Here, we discuss the elements regulating embryonic erythropoiesis with special attention to niche cells, and demonstrate how this knowledge can be applied in the identification of niche-derived peptides with potential therapeutic capability.

Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study

Atsushi Otsuka,Takahisa Suzuki,Yuto Matsushita,Hiromitsu Watanabe,Keita Tamura,Daisuke Motoyama,Toshiki Ito,Takayuki Sugiyama,Hideaki Miyake 대한배뇨장애요실금학회 2019 International Neurourology Journal Vol.23 No.4

Purpose: To evaluate whether hydrodistention with fulguration of Hunner lesions (HD/FUL) plus maintenance dimethyl sulfoxide (DMSO) therapy prolongs the recurrence-free time in patients with Hunner type interstitial cystitis (IC). Methods: The study enrolled patients with Hunner type IC who required repeat HD/FUL due to recurrence of IC symptoms after the first HD/FUL at our institution. All patients received a second HD/FUL plus maintenance DMSO therapy. The maintenance DMSO therapy was performed every 2 weeks for a total of 8 instillations, and then once every 4 weeks thereafter. The recurrencefree time from HD/FUL to therapeutic failure was estimated using the Kaplan-Meier method. The recurrence-free time between the first HD/FUL and second HD/FUL plus maintenance DMSO therapy was statistically compared using the log-rank test. Results: A total of 21 patients (mean age, 66.3±10.8 years) with Hunner type IC were evaluated. The recurrence-free time for the second HD/FUL plus maintenance DMSO therapy was significantly longer than that for the first HD/FUL (P<0.0001). The median recurrence-free time for the first HD/FUL was 10.1 months, while that for the second HD/FUL plus maintenance DMSO therapy has yet to be reached. The recurrence-free rate for the first HD/FUL was 81.0% at 6 months, 38.1% at 1 year, 9.5% at 2 years, and 4.8% at 3 years. In contrast, the rate for the second HD/FUL plus maintenance DMSO therapy was 100% at 6 months, 94.7% at 1 year, 82.6% at 2 years, and 82.6% at 3 years. There were no significant differences in efficacy between the first and second HD/FUL. Conclusions: HD/FUL plus maintenance DMSO therapy clearly prolongs the recurrence-free time compared with HD/FUL alone in Hunner type IC.